or Try an Advanced Search...

    Central Nervous System Disorders Stocks List

    Symbol Grade Name % Change
    NRXP F NeuroRx, Inc. 2.44
    PASG F Passage Bio, Inc. -5.78
    NGNE F Neurogene, Inc. 30.21
    IRWD F Ironwood Pharmaceuticals, Inc. 2.99
    SAGE F Sage Therapeutics, Inc. 6.60
    BNOX F Bionomics Limited 6.01
    View As Page of Charts
    Related Industries: Biotechnology Conglomerates Drug Manufacturers - Specialty & Generic
    Related Stock Lists: Nervous System Disorders Antidepressants Biopharmaceutical Drugs Rare Diseases Treatment Of Central Nervous System Disorders Adjunctive Therapy Alzheimer's Disease Anticonvulsants Antineoplastic Drugs Anxiolytics Atypical Antipsychotics Biotechnology Bipolar Depression Bipolar Disorder Camidanlumab Tesirine Cancer Cancer Treatment Cardiovascular Disease Chronic Idiopathic Constipation

    Related ETFs - A few ETFs which own one or more of the above listed Central Nervous System Disorders stocks.

    Symbol Grade Name Weight
    PSIL C AdvisorShares Psychedelics ETF 4.78
    MEDX F Horizon Kinetics Medical ETF 0.79
    QQQS B Invesco NASDAQ Future Gen 200 ETF 0.78
    BBP C BioShares Biotechnology Products Fund 0.65
    BIS C ProShares UltraShort Nasdaq Biotechnology 0.48
    View all Central Nervous System Disorders ETFs...
    Compare ETFs
    Compare BBP to BIS Compare MEDX to QQQS Compare PSIL to QQQS

        Central Nervous System Disorders Stocks Recent News

        Date Stock Title
        Nov 22 SAGE Sage Therapeutics price target lowered to $4 from $7 at BofA
        Nov 21 SAGE Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
        Nov 21 SAGE Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
        Nov 21 SAGE Sage ends dalzanemdor development following Phase II trial failure
        Nov 21 SAGE SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
        Nov 21 SAGE Sage raised to sector perform by RBC in wake of drug failure
        Nov 20 SAGE After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder
        Nov 20 SAGE Sage slips as Huntington’s Disease therapy fails in mid-stage trial
        Nov 20 SAGE Sage’s string of research failures continues
        Nov 20 SAGE Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
        Nov 19 SAGE CNS Drug Development: Same As It Ever Was
        Nov 19 NGNE Neurogene GAAP EPS of -$1.19 in-line
        Nov 18 NGNE Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
        Nov 18 BNOX Bionomics files for $100M mixed securities shelf
        Nov 18 NGNE How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
        Nov 18 NGNE Neurogene stock plunges 36% on NGN-401 study update
        Nov 18 NGNE Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
        Related Industries: Biotechnology Conglomerates Drug Manufacturers - Specialty & Generic
        Related Stock Lists: Nervous System Disorders Biopharmaceutical Clinical Development Depression Depressive Disorder Major Depressive Disorder Organic Compounds Pyridines Schizophrenia Treatment Of Central Nervous System Disorders Treatment Of Major Depressive Disorder Acute And Chronic Pain Acute Pain Adjunctive Therapy Alcohol Alzheimer's Disease Analgesics Anticonvulsants Antidepressants Antisense RNA
        Central Nervous System Disorders

        Central Nervous System Disorders are conditions that affect the brain, spinal cord, and nerves. These disorders can cause a wide range of symptoms, including impaired movement, vision, speech, and sensation. Examples of Central Nervous System Disorders include Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and stroke.

        Browse All Tags